Table 1.

Susceptibility of clinical isolates of enterococci used in this study to opsonic killing mediated by rabbit antiserum toE. faecalis 12030

StrainSourcea% of bacteria killed by antisera to strain 12030b
E. faecalis
 12030Cleveland, Ohio, VA96
 12107Cleveland, Ohio, VA37
 9693Cleveland, Ohio, VA0
 JH2-2Laboratory strain0
 R19.001CH26
 I.006CH0
 355974LBIDMC47
 334802KBIDMC91
 326578KBIDMC47
 324057BBIDMC0
 175-ABWH79
 10688330ABWH21
 6814BWH0
 1067761BWH61
 B8597ABWH35
 B8610ABWH0
Vancomycin-resistant E. faecium
 838970BWH83
 755221BWH28
 824955BWH23
 B210860BWH9
 740220BWH18
 757875BWH25
 805370BWH60
  • a VA, Veterans Administration Hospital (courtesy of David Shlaes); CH, Children’s Hospital, Boston, Mass.; BIDMC, Beth Israel Deaconess Medical Center, Boston, Mass.; BWH, Brigham and Women’s Hospital, Boston, Mass. Note that BIDMC and BWH isolates were all distinct by pulsed-field gel electrophoresis analysis.

  • b Killing of >45% is significant at P ≤ 0.05 by t test comparing CFU surviving in immune sera with CFU surviving in nonimmune sera (significant results shown in boldface type).